Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29860886 | 0.94 | CA1 (0.52) | HSD11B1CYP2C9USP30PARP1CA1 | |
| SCHEMBL29123195 | 0.94 | CA1 (0.52) | HSD11B1CYP2C9USP30PARP1CA1 | |
| SCHEMBL2952653 | 0.94 | CA1 (0.52) | HSD11B1CYP2C9USP30PARP1CA1 | |
| SCHEMBL30349744 | 0.93 | USP30 (0.52) | HSD11B1CYP2C9USP30PARP1BRD4 | |
| SCHEMBL14428332 | 0.89 | KMT2A (0.44) | HSD11B1CYP2C9 | |
| SCHEMBL6010052 | 0.87 | USP30 (0.54) | USP30PARP1CA1CA2BRD4 | |
| SCHEMBL29641323 | 0.87 | KCNA3 (0.44) | HSD11B1CYP2C9PARP1CTSKKCNA3 | |
| SCHEMBL30171776 | 0.86 | BACE1 (0.49) | USP30PARP1CA1CA2 | |
| SCHEMBL17997424 | 0.86 | BACE1 (0.49) | USP30PARP1CA1CA2 | |
| SCHEMBL29625116 | 0.86 | BACE1 (0.49) | USP30PARP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087466-A1 | NOVEL SMALL MOLECULE DNAK INHIBITORS | CHAPERONE TECHNOLOGIES, INC. | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087466-A1 | NOVEL SMALL MOLECULE DNAK INHIBITORS | HSP90AB2P, HSPH1, HSP90AB1 | HSD11B1 3392/4885CYP2C9 4500/4885USP30 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.